Last checked at 16 Aug 2018 07:00
16 August 2018
Nuformix Plc
("Nuformix" or the "Company")
2018 Annual Financial Report and Notice of Annual General Meeting
The Company announces that the following documents were posted to its shareholders:
· Annual Financial Report 2018
· 2018 Notice of Annual General Meeting and Proxy Form
A full pdf version of the Annual Financial Report 2018 together with the Notice of Annual General Meeting and sample Proxy Form are available for download from the Document Center section on the Company's website www.nuformix.com.
Copies of the Annual Financial Report 2018 and the Notice of 2018 Annual General Meeting and Proxy Form have been submitted to the National Storage Mechanism and will be available for inspection in due course at http://www.morningstar.co.uk/uk/NSM. The Nuformix Annual Financial Report will be filed with the Registrar of Companies in due course and copies can be obtained from the Company Secretary, SGH Company Secretaries Limited, 60 Gracechurch Street, London, EC3V 0HR.
The Annual General Meeting will be held on Wednesday 19 September 2018 at 1.00 pm at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.
For further information please contact:
Nuformix plc
Dan Gooding, Chief Executive Officer
+44 (0)1223 423 667
SGH Company Secretaries Ltd
Ben Harber
+44 (0)207 264 4366
Gable Communications Ltd
John Bick or Justine James
+44 (0)20 7193 7463
About Nuformix plc: www.nuformix.com
Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix's risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.
Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.
Nuformix was established in Cambridge in 2009 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.